Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
NEW YORK, Jan. 23, 2024 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Gerard Michel, CEO, will participate in a fireside chat moderated by Bill Maughan Ph.D., Senior Analyst at Canaccord Genuity, at the Lytham Partners 2024 Investor Select Conference. Management will also host virtual one-on-one meetings with investors.
Related news for (DCTH)
- Delcath Systems Reports First Quarter 2025 Results and Business Highlights
- 24/7 Market News Snapshot 08 May, 2025 – Delcath Systems Inc (NASDAQ:DCTH)
- Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
- 24/7 Market News Snapshot 13 January, 2025 – Delcath Systems Inc (NASDAQ:DCTH)
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results